Resistance and resilience to Alzheimer's disease in Down syndrome.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Due to the high prevalence of Alzheimer's disease (AD) in adults with Down syndrome (DS), trisomy 21 is now considered a genetic form of AD (DSAD). A better understanding of factors that can prevent or delay AD is vital to improve outcomes for adults with DS. In this narrative review, we apply AD and cognitive aging research frameworks to study resistance and resilience in DSAD. Given the variability in the timing of pathology and symptoms, we discuss the evidence supporting the role of genetic, biological, socio-behavioral, lifestyle, and environmental factors in resistance and resilience to DSAD. We also consider how co-occurring health conditions in DS may influence resistance and resilience, and how methods from AD research can be applied to DSAD. Ultimately, this framework aims to guide future research and translate findings into clinical interventions to improve outcomes in DSAD. Highlights Definitions of resistance and resilience in the genetic form of Alzheimer's disease (DSAD) are proposed for guiding the field. Variability in the timing of AD pathology and symptoms suggests the potential for resistance and resilience mechanisms in DSAD. Genetic, biological, socio-behavioral, lifestyle, and environmental factors have the potential to build resistance or resilience in DSAD. Future research will require longitudinal and experimental designs, life course approaches, and large cohort studies.
Description
Publication status: Published
Funder: Una Manera de Hacer Europa
Funder: Department de Salut de la Generalitat de Catalunya
Funder: Fondo de Investigaciones Sanitario
Funder: University of Nebraska, and Central States Center for Agricultural Safety and Health
Funder: Fondo de Investigaciones Sanitario, Carlos III Health Institute
Funder: Fondo Europeo de Desarrollo Regional, Una Manera de Hacer Europa, Department de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca I Innovació en Salut
Funder: European Union; doi: http://dx.doi.org/10.13039/501100000780
Funder: Alzheimer's Society United Kingdom
Funder: Jerome Lejeune Foundation; doi: http://dx.doi.org/10.13039/100007353
Funder: Spanish Ministry of Science and Innovation, European Social Fund—State Research Agency
Journal Title
Conference Name
Journal ISSN
1552-5279
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
Barcelona City Council, Fundació La Caixa (21S09060, 23S06157‐001)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2018/15167)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (302527/2022‐2)
National Institutes of Health (R01AG079142, DP2AG082342, K01AG084816, R21AG075643, R61 HD100973, R01AG066159, R21AG075643, K99AG083063, AARG21850839, U19AG068054, RF1AG079519, R00AG065506, P30AG066519, RF1AG079519, RF1AG060472, U19AG068054, P30AG066519, 1R01AG070028, U19AG033655, P50AG005146, R01AG056850, R21AG056974, R01AG061566, R01AG081394, R61AG066543, U01AG024904)
Jerome Lejeune Foundation, Alzheimer's Society United Kingdom (ASPG213)
MRC Program Grant (MR/N029941/1)
Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP‐DOW‐2020‐151)
Pla Estratègic de Recerca I Innovació en Salut (SLT006/17/00119)
Salud Carlos III Sara Borrell (SBCD23/00235, CP20/00038)
Carlos III Health Institute (INT21/00073, PI20/01473, PI23/01786, PI22/00307)
Alzheimer's Association (AARG2019‐AARG‐644641, 23AARFD‐1022715, 23AARF‐1026796, AARG‐22‐923680)